496
Participants
Start Date
October 11, 2023
Primary Completion Date
February 28, 2026
Study Completion Date
February 28, 2026
Regorafenib in combination with pembrolizumab
Randomized patients will receive regorafenib at a dose of 90 mg per day by mouth on days 1 to 21 of a 28-day cycle, in combination with pembrolizumab 400 mg using a 30-minute intravenous infusion, on day 1 (D1) of a 6-week cycle.
Loco-regional therapy
"Patients will be treated with TACE or TARE on-demand according to site's standard of practice."
Chang Gung Memorial Hospital - Linkou, Taoyuan District
UCL SAINT LUC - UC Louvain, Brussels
Antwerp University Hospital, Edegem
JSC VIANI Batumi Referral Hospital, Batumi
Gülhane Eğitim ve Araştırma Hastanesi, Ankara
Gazi University MF, Ankara
National Taiwan University Hospital, Taipei
Institue of Oncology Vojvodine Sremska Kamenica (Oncology Institute of Volvodina), Kamenitz
Institutul Clinic Fundeni, Bucharest
Hospital Universitario La Paz, Madrid
Koc University Hospital, Istanbul
Hospital Universitario Miguel Servet, Zaragoza
CHU Amiens-Picardie, Amiens
UCLA Santa Monica Hematology Oncology, Santa Monica
Hôpital Beaujon - APHP, Clichy
Hôpital Henri Mondor, Créteil
Ospedale Garibaldi Nesima, Catania
"Regional Institute of Gastroenterology and Hepatology Dr Octavian Fodor", Cluj-Napoca
Center of Oncology Euroclinic Victoria Hospital, Iași
Humanity and Health Clinical Trial Center, Hong Kong
Israel-Georgian Medical Research Clinic Healthycore, Tbilisi
Universitätsmedizin: Medizinische Klinik und Poliklinik I, Mainz
Clinic for Digestive Surgery, University Clinical Center of Serbia, Belgrade
Inje University Haeundae Paik Hospital, Busan
Cha Bundang Medical Center, Seongnam-si
Severance Hospital, Yonsei University Health System, Seoul
Collaborators (1)
Bayer
INDUSTRY
Translational Research in Oncology
OTHER